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Background: There is uncertainty about the most important indicators of pulmonary exacerbations in CF.
Methods: Two parallel Delphi surveys in 13 CF centres (UK and Ireland). Delphi 1: 31 adults with CF, ≥one exacerbation over 12 months. Delphi
2: 38 CF health professionals. Rounds 1 and 2 participants rated their level of agreement with statements relating to indicators of exacerbation;
Round 3 participants rated the importance of statements which were subsequently placed in rank order.
Results: Objective measurements were of higher importance to health professionals. Feelings of increased debility were rated most important by
adults with CF.
Conclusions: There were clear differences in perspectives between the two groups as to the most important indicators of an exacerbation. This
highlights that CF health professionals should take more cognisance of speciﬁc signs and symptoms reported by adults with CF, especially since
these may be a precursor to an exacerbation.
© 2014 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.
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Pulmonary exacerbations (PEXs) in cystic fibrosis (CF) are
associated with disease progression, increased morbidity, mor-
tality, and substantial healthcare costs [1–4]. PEXs are experi-
enced by a large proportion of patients with CF. The most recent
annual information from the CF Registry of Ireland reported 451
paediatric admissions and 680 adult admissions for a PEX treated⁎ Corresponding author at: Northern Ireland Clinical Trials Unit (NICTU), 1st
Floor Elliott Dynes, The Royal Group of Hospitals, Grosvenor Road, Belfast
BT12 6BA, United Kingdom. Tel.: +44 2890 63 1903.
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1 Joint ﬁrst authors.
2 Joint senior authors.
http://dx.doi.org/10.1016/j.jcf.2014.06.007
1569-1993© 2014 Published by Elsevier B.V. on behalf of European Cystic Fibroswith intravenous antibiotics, using data that was available for
881 registered patients [5]. The CF Registry of the UK reported
3732 paediatric lung infections and 5062 adult lung infections
using data that was available for 8794 registered patients [6].
Minimising PEXs is critical for the long term health of adults
with CF since patients who have more than two PEXs per year
have a significantly reduced three year survival compared to
those who have one or none [4]. PEXs are associated with a
more rapid decline in FEV1, which results in a further decline in
overall wellbeing [7,8]. Health related quality of life (HRQoL)
worsens during PEX and more severe exacerbations have a
greater negative impact on HRQoL [1,8]. Most people with CF
die of respiratory failure which has typically been induced by a
PEX [9–11].is Society.
91F. McCourt et al. / Journal of Cystic Fibrosis 14 (2015) 90–96PEXs are also frequently used as an end point in clinical
trials and recommended by European Medicines Agency
(EMA) and Food and Drug Administration (FDA) as primary
efficacy end points [2,12–14]. However, neither agency mandates
any definition of a PEX. Consequently definitions used in clinical
trials are multiple and are inconsistent with each other [15]. In
addition, they often show inconsistencies with criteria routinely
used by CF health professionals [16–18].
Previously it was suggested that the Delphi technique is an
appropriate methodology to identify which criteria should be
included in a definition of a PEX in CF [17]. This technique uses
a series of repeated surveys to gain consensus on a given issue
[19–22].
This method reduces peer pressure and encourages unbiased
responses, as participants remain anonymous to the core members
of the research team and to other participants [19,21–23]. The
Delphi technique is a practical, efficient, inexpensive and widely
used consensus research method in health care research [24,25].
The aim of this study was to identify the important indicators
of an exacerbation determined by a group of adults with CF and a
group of CF health professionals.
2. Methods
2.1. Design and recruitment
Two parallel Delphi surveys were used to investigate agreement
among a group of adults with CF and CF health professionals
regarding the important indicators of an exacerbation.
This was a multicentre study across the UK and Ireland.
Twenty-seven CF centres were approached to take part aiming
to recruit two to three adults with CF and two to three CF healthFig. 1. Summary of the stages of the Delphi surveys.professionals per centre. Participants were identified by a
designated key health professional at each CF centre who was
responsible for ensuring that all participants met the inclusion
criteria for their participant group. The inclusion criteria for
adults with CF were: confirmed diagnosis of CF, over 18 years,
FEV1 less than or equal to 80% predicted, experienced at least
one exacerbation requiring IV antibiotics in the previous
12 months and computer literate with internet access available
for the duration of the study. The inclusion criteria for CF
health professionals were: CF health professionals working
in adult CF centres in the UK/Ireland, currently involved in
assessing if CF patients are having an exacerbation and
deciding a treatment plan and computer literate with internet
access available for the duration of the study.
The stages of this Delphi survey are summarised in Fig. 1.
Ethical approval was obtained from the Office for Research
Ethics Committees Northern Ireland. Research governance was
sought at participating sites. Data collection took place over a
seven month period (Sept 2010–April 2011). In each round non
responders were followed up and sent weekly reminders to
complete the survey.2.2. Delphi Round 0: statement generation
The aim of Round 0 was to generate a list of statements for
Round 1 of the Delphi survey. The first step in developing the
Delphi survey for this study was to conduct a systematic literature
search and extract criteria used to identify an exacerbation. This
search identified 218 criteria from 86 articles. However, there
were many similarities in the terminology used, consequently
criteria that were similar in meaning were grouped together toKey. Health professionals: HPs, cystic fibrosis: CF.
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31 themes, which were then agreed by the research team.
The themes were built further through the results of patient
interviews with 47 adults with CF to identify their perception of
the indicators of an exacerbation and a review of CF specific
quality of life instruments [16,26,27]. While these questionnaires
are assessing quality of life, they contain signs, symptoms and
feelings that are related to people with CF and are used in clinical
trials and in clinical practice to help identify the health status of
patients which were not already covered by the themes identified.
The agreed themes were used to formulate statements for
“Round 1” of the Delphi survey. Finally, health professionals at
the Belfast CF centre independently reviewed the statements. A
few minor changes were made. One issue related to haemoptysis
can have a range of severity levels . It was agreed that it should be
represented as two separate statements: ‘Sputum streaked with
blood’ and ‘Frank haemoptysis’ (referred to as ‘Coughing up
blood’ in the adults with CF survey). Although it was recognised
that haemoptysis is not a particularly common feature of
exacerbations in CF, clearly frank bleeding is of concern. The
research team therefore agreed that inclusion of two statements
was sufficient when considering this potential sign.
The statements were then piloted with several adults with CF
to ensure clarity of the wording. The research team recognised
that there is some overlap between some of the statements used
in the Delphi survey, however, this was partly a result of
the feedback from the adults with CF. For example, they
considered that there was a distinction between the statements,
“Feeling more short of breath than usual” and “Trouble
breathing” and advised that they should remain as distinct
statements. The adults with CF also provided their views on
different response formats recommended for use in Delphi
methodology in order to inform the preferred response format
for this survey and to finalise the survey [22]. Two surveys
with statements (n = 48) focussing on indicators of PEX were
compiled, one for adults with CF and one for CF health
professionals. The only difference was in the use of lay
terminology in the patient survey e.g. instead of haemoptysis
“Sputum streaked with blood” was used.2.3. Delphi Round 1
Two Delphi surveys were administered simultaneously using
the web based survey tool ‘Survey Monkey’ [28]. Both
participant groups were given the same survey in Round 1, the
only difference being that, where appropriate, the terminology
was provided in lay terms for the adults with CF. Participants
were asked to rate their level of agreement with each statement
using a five point Likert scale (strongly agree, agree, neither agree
nor disagree, disagree, strongly disagree) with an additional
option of “don't know”. For example, participants were asked
to indicate their agreement with the statement that “Feeling
more tired than usual, is an important indicator of pulmonary
exacerbation”. There was also an open question where partici-
pants were able to add additional criteria/items to avoid missing
any important issues.2.4. Delphi Round 2
In Round 2 statements from Round 1 that did not reach
consensus (defined as 75% agreement), along with five additional
statements identified from the open question were presented to
both groups. In Round 2, the adults with CF survey contained 32
statements and the CF health professional survey contained 30
statements. Participants were also provided with a summary of
the results from Round 1 for their participant group; this included
their individual original response, the group response, and a
summary chart showing the responses to that particular statement.
Participants were asked to reconsider the statement again, taking
into account the feedback of results from Round 1, and to re-rate
their level of agreement with each statement. They were advised
that they did not have to change their response if they did not wish
to. There were five additional statements developed from the open
question in Round 1 which were also presented as new statements
using the original format from Round 1.2.5. Delphi Round 3
In Round 3 participants were presented with statements that
had reached 75% agreement in Round 1 or 2. Both surveys
contained 35 statements (adults with CF survey: 31 statements
along with four additional statements to rate that had only reached
consensus in the health professional survey; CF health profes-
sional survey: 30 statements along with five additional statements
to rate that had only reached consensus in the adults with CF
survey). Participants were asked to rate the level of importance on
a scale of one to 10, where one represented the lowest level of
importance and ten represented the highest level of importance.2.6. Data analysis
The data generated from each round was analysed with
SPSS 17.0 using descriptive statistics. The data from each
participant group was analysed separately. The researcher
summarising the data from all rounds was blinded to the study
participant's identity. In order to identify which statements had
reached consensus in Round 1 or Round 2 the percentage
agreement and median response were calculated. In Delphi
surveys the level of consensus is determined prior to initiating
data collection, and this can vary depending on the topic being
investigated. A consensus level of 75% was selected following
guidance from the literature; this meant including responses
where a person had indicated that they ‘strongly agree’ or
‘agree’ [21]. For Round 3 results were analysed by applying a
rating average and then placing criteria in a ranked order of
importance, in order to identify factors of importance within
each group and to facilitate comparison between the groups.
Further analysis was conducted in Round 3 to identify if
the differences for individual statements between the groups were
statistically significant, using the independent t-test for statements
with normally distributed data and theMann–WhitneyU test was
used for data which was not normally distributed.
93F. McCourt et al. / Journal of Cystic Fibrosis 14 (2015) 90–963. Results
The CF centres that participated in this study were identified
through the CF Trust website (www.cftrust.org.uk) and the CF
Association of Ireland website (www.cfireland.ie). The centres
were all specialist CF centres providing care for adults with CF.
All 27 centres identified were invited to participate in the study
and data was obtained from 13 (48%) centres. Of the 14 centres
that did not participate, seven declined due to a variety of
reasons including commitments to other studies or staffing
restraints, five did not respond, and two agreed initially but due
to difficulties with their local research governance approval
they were unable to take part.
In Round 1, 31 adults with CF with moderate to severe
disease completed the survey. The participants ranged from
age 23 to 52 years. All participants confirmed that they had
experienced at least 1 exacerbation in the previous year
(defined by their centre) and were treated with IV antibiotics.
The number of exacerbations reported by the adults with CFTable 1
Indicators of an exacerbation from a Delphi survey in adults with CF: mean scores,
Statement
A large decrease in lung function (greater than 10% FEV1)
Feeling more short of breath than usual
Trouble breathing
Feeling the need to do more airway clearance than usual
An increase in symptoms at night
Producing more sputum
Finding it harder than normal to do your usual exercise
Finding it harder than normal to do your usual activities
Feeling more exhausted than usual
More coughing than usual
A change in the colour of your sputum
More wheezing or chest tightness
Feeling more fatigue than usual
Generally feeling unwell
Breathing at a faster rate than usual
Thicker sputum than usual
Less energy than usual
Feeling more tired than usual
Having to use more inhaled medications (i.e. inhalers, mucolytics) than usual
Knowing you have an increase in the infection markers in your blood (for example
Knowing that your oxygen levels are low
More chest pain than usual
Coughing up blood
Knowing that you have a decrease in your oxygen saturation (measured with a fing
Increased time spent resting
Sputum that is harder to cough up
Fever or increased temperature
A change in the taste of your sputum
Loss of appetite
Knowing that you have new bacteria in your sputum
Generally looking unwell
Knowing that you have new additional breath sounds when your chest is examined
Sputum streaked with blood
Weight loss
Knowing that you have new changes on chest x-ray
Bold = the top 10 statements ranked.
Note: Scores with the same average rating were given the same joint ranked positio
a Also ranked in the top 10 by CF HPs.were 1–3 n = 17; 4–6 n = 11; and N6 n = 3. A lung function
(FEV1%predicted) of less than 40% was reported by 11
participants and 8 participants reported a lung function of 40–
60%. In Rounds 2 and 3 the surveys were completed by 28 and
27 participants respectively.
All 38 CF health professionals who registered completed all
survey rounds. Their professions are as follows: nurse n = 13,
physiotherapist n = 6, dietician n = 1, and doctor n = 18.
By the end of Round 2, 31 statements from adults with CF,
and 30 statements from CF health professionals, had reached
consensus (Fig. 1). In Round 3 there were clear differences
between adults with CF and CF health professionals as to the
important indicators of an exacerbation. Tables 1 and 2 show
the mean scores, standard deviation and rating order for all the
statements (adults with CF and health professionals) from
Round 3. Indicators from the adults with CF that were rated of
higher importance were commonly rated lower by CF health
professionals; for example, “An increase in symptoms at night”
was rated higher by adults with CF (rank order 5) and lower bystandard deviation and rank order of each statement.
Mean score Std. deviation Rank order
9.33 0.784 1 a
8.52 1.087 2 a
8.52 1.805 2
8.37 1.115 4
8.22 1.450 5
8.19 1.388 6 a
7.96 1.581 7
7.93 1.838 8
7.85 1.703 9
7.85 1.610 9 a
7.78 1.601 11
7.7 1.815 12
7.59 1.760 13
7.59 1.716 13
7.48 1.805 15
7.44 2.082 16
7.41 1.600 17
7.37 1.779 18
7.33 2.287 19
CRP, white cell count) 7.33 2.201 19
7.33 2.130 19
7.33 2.434 19
7.15 2.231 23
er probe) 7.15 2.013 23
7.11 1.672 25
7.11 1.888 25
7.07 2.183 27
7.04 2.047 28
6.93 1.859 29
6.81 2.095 30
6.81 2.113 30
6.78 1.888 32
6.7 1.728 33
6.59 1.947 34
6.56 1.888 35
n.
Table 2
Indicators of an exacerbation from a Delphi survey in CF health professionals: mean scores, standard deviation and rank order of each statement.
Statement Mean score Std. deviation Rank order
Increased sputum 8.84 1.027 1 a
A large decrease in lung function (greater than 10% FEV1) 8.84 1.263 1
a
More shortness of breath than usual 8.32 1.141 3 a
Increased inflammatory markers (for example CRP and white cell count) 7.92 1.124 4
Fever or increased temperature 7.89 1.269 5
Increased respiratory rate at rest 7.82 1.557 6
Decreased oxygen saturation 7.79 1.510 7
Hypoxia/hypoxemia 7.76 1.807 8
Change in the colour of sputum 7.61 1.636 9
New changes on chest X-ray 7.47 1.767 10
Increased coughing 7.47 1.466 10 a
Trouble breathing 7.42 1.500 12
Haemoptysis (blood streaked sputum) 7.34 1.760 13
Decreased exercise tolerance 7.32 1.416 14
Feeling the need to do more airway clearance than usual 7.21 1.379 15
New added breath sounds on auscultation 7.08 1.807 16
Frank haemoptysis (fresh blood) 7.08 2.306 16
Increased thickness (viscosity) of sputum 7.05 1.559 18
Having to use more inhaled medications (i.e. inhalers, mucolytics) than usual 7.03 1.197 19
Difficulty performing usual activities 6.74 1.655 20
Feeling more tired than usual 6.71 1.575 21
Increased wheeze or chest tightness 6.66 1.419 22
Difficulty clearing sputum 6.66 1.475 22
Generally feeling unwell 6.63 1.601 24
Feeling more fatigue 6.58 1.571 25
Weight loss 6.5 1.928 26
Feeling more exhausted than usual 6.47 1.640 27
Decreased appetite 6.29 1.541 28
Increased symptoms at night 6.26 1.884 29
Lack of energy 6.24 1.532 30
Chest pain 6.11 1.721 31
Change in the taste of sputum 5.92 1.978 32
Generally looking unwell 5.89 1.813 33
Increased time spent resting 5.76 1.667 34
New bacteria in sputum 5.5 2.153 35
Bold = the top 10 statements ranked.
Note: Scores with the same average rating were given the same joint ranked position.
a Also ranked in the top 10 by adults with CF.
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health professionals that were rated high were commonly
rated lower by patients with CF; for example “haemoptysis
(blood streaked sputum)” was rated higher by CF health
professionals (rank order 13) and lower by adults with CF
(rank order 33).
It is difficult to select a cut off point however; few
statements were rated high by both groups. For example the
top ten indicators from the adults with CF, six of these were not
ranked in the top 10 by CF health professionals. In the top 10
indicators from the CF health professionals, six of these were
not ranked in the top 10 by adults with CF. The four statements
in the top 10 where there was agreement were “A large decrease
in lung function (Greater than 10% FEV1)”, “Feeling more
short of breath than usual”, “Producing more sputum than
usual” and “More coughing than usual”. Although FEV1, is an
objective indicator it is perhaps not surprising that it appeared
as the top item on the adults with CF list, since there is a
big emphasis on this measurement in the clinic. Examinationof the standard deviations for each of the indicators showed that
there was reasonably good agreement for individual criteria,
although there was a trend to a reduced level of consensus
in the less highly rated criteria. Following analysis via
the independent t-Test or Mann–Whitney U, there were 15
statements in Tables 1 & 2 which showed a statistically
significantly different rating with a p-value b0.05. While it is
interesting to note results which were significantly different
this was, of necessity, a semi-quantitative study. While a
certain degree of importance can be placed on the statistical
significance, the research team felt that more importance should
be placed on the clinical relevance which is detailed through the
hierarchy of average rating scores for each group.
4. Discussion
This study has used a series of surveys, including an initial
systematic analysis of the literature, to clarify what are the key
criteria for identifying a PEX in CF. It has demonstrated that
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different hierarchy of important indicators of PEX. In general,
the important indicators identified by the adults with CF were
more subjective than those identified by the health profes-
sionals, who preferred more objective clinical measurements
(Tables 1 and 2). The importance of physiological measure-
ments, such as oxygen saturation, to CF clinicians has recently
been reported in a study using clinical vignettes to identify
exacerbation criteria [18]. However, often the relationship between
changes in physiological measurements and changes in symptoms
and function in people with respiratory conditions is weak, and this
may help to explain why patients have different criteria than health
professionals.
It is not surprising that the two groups identified different
hierarchies of importance for the signs and symptoms since they
have access to different information; the patients experience
symptoms, whereas the health professionals observe or measure
them, or rely on patient reporting whichever symptoms they think
are relevant, possibly in response to specific questioning by the
clinician. A more defined series of questions and/or tests might
help to improve information gathering. The timing of when
indicators of an exacerbation occur could also be relevant, as
symptoms may be apparent to patients which later trigger the
health professionals to evaluate with objective investigations.
This highlights that CF health professionals should consider the
signs and symptoms described by an adult with CF; this is
especially pertinent when the patient indicates that a specific
symptom is often a likely precursor to an exacerbation in their
condition.
Currently available criteria-based definitions only capture
some of the indicators that were rated important in our study [15].
For example, indicators such as “Feeling the need to do more
airway clearance than usual” which was considered important by
adults with CF in our study are not in current criteria. Also
indicators in our study such as “Increased inflammatory markers”
considered important by health professionals are not in the current
criteria [15]. Other indicators of PEX such as the four that adults
with CF and CF health professionals agreed were important
(Tables 1 and 2) are captured in current definitions. These
variations represent the complexity involved in developing an
agreed definition and resulting clinical tool(s) or research tool.
However, attempting to define an exacerbation in CF continues to
be relevant because the presence/absence of an exacerbation is
recognised by EMA as an important end point [14].
A single set of criteria may not be the most useful in defining
an exacerbation in CF. It may be more accurate to identify an
individual set of signs and symptoms of a PEX for each patient;
the extent of the deviation from their “usual signs and symptoms”
could then be used to identify an exacerbation. This could be
valuable to enable patients to share their management with their
health professional, and perhaps incorporate an action plan
relating to monitoring usual symptoms and recognising the onset
of an exacerbation. It could help clinical teams to standardise the
criteria used for admission to hospital with an exacerbation and
with decisions around commencing oral or IV antibiotics, or
more intensive therapy. If the criteria were useful in establishing
the severity of the exacerbation this could help with decisionsaround treatment delivered at home versus hospital. It could also
have a research utility in assessing the response of specific
therapies in limiting the severity of exacerbations by bench
marking efficacy against clearly identified personalised criteria
for each individual patient. This is generally what CF clinicians
do informally as part of clinical reasoning, and it would be helpful
if this was formalised into a tool that could be used by patients at
home and in clinical trials.
Further research is required to build on the findings of this
study. It is notable that the signs and symptoms that prompt adults
with CF to seek medical attention are often different from those
consideredmost important by the health professionals. Therefore,
a dialogue between clinicians and patients should be encouraged
to help individuals identify which signs and symptoms are critical
for them in identifying the onset of a PEX. The aim would be to
promote earlier engagement with their CF centre which could
result in earlier intervention and triage of treatment options. The
results of this study could also be used to explore if the criteria
selected by CF health professionals provide scope for helping to
determine treatment plans. A clinical tool may be an appropriate
way forward. For example, the Chronic Respiratory Disease
Questionnaire (CRDQ) enables patients to identify up to 5
activities which induce breathlessness; in the same way a clinical
tool for defining PEX could consider 5 (or more) criteria
which individual patients select as important in defining their
exacerbation [29]. A new tool could also incorporate objective
indicators that health professionals consider important. For
example, the Asthma Control Questionnaire incorporates
patient's views on whether their asthma is under control as well
an objective measurement of peak respiratory flow rate [30]. Any
new tool should consider that different indicators of a PEX may
be associated with different degrees of disease severity and also
different severities of exacerbation [16].
Despite the high response rate with 94% of participants
completing all three rounds of the Delphi, a limitation of
this study is the small sample size. However, this study
included a large spread of centres across the British Isles
giving confidence that we obtained a representative range of
experience from CF centres of different sizes and localities.
In Delphi studies it is proposed that the consensus level be
defined in advance of acquiring the data so that the researchers
cannot influence the outcome of the survey [22]. The 75%
consensus level was chosen through reference to previously
published Delphi studies but the choice of a specific consensus
level is an aspect of Delphi methodology that remains contentious
[22]. The validity of this study was optimised by providing
explicit participant inclusion criteria, pilot testing, setting a
predetermined consensus level, and monitoring the number
of rounds [20–23].
5. Conclusions
This study used a Delphi consensus method to ascertain
important indicators of PEX from the perspectives of adults with
CF and CF health professionals. There were clear differences in
perspectives between the two groups in relation to the important
indicators of an exacerbation in CF.
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